samedan logo
 
 
spacer
home > ebr > winter 2002 > novel antibiotics to counteract the global threat of superbugs
PUBLICATIONS
European BioPharmaceutical Review

Novel Antibiotics to Counteract the Global Threat of Superbugs

The introduction of antibiotics in the 1950s and 1960s revolutionised medicine, to such an extent that in 1969 the US Surgeon General famously declared: "The time has come to close the book on infectious disease". Following this initial optimism, many companies left the field. While industry dollars were spent elsewhere, bacteria became resistant to antibiotics at a rapid pace. Despite renewed efforts in antibiotic discovery, resistance is now a global threat to public health.Changing population demographics, increasing use of invasive procedures, the spread of HIV, an increasing number of immunocompromised patients and misuse of broad spectrum antibiotics have meant that new pathogens have emerged, some of which are resistant to one or several of the antibiotics normally used to treat them (1).


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Anne Gill, Head of Microbiology at PanTherix Ltd Anne Gill obtained her PhD in Medical Microbiology from the University of Edinburgh, specialising in the mechanisms of antibiotic action and resistance. After conducting post-doctoral research, Anne joined PanTherix, where she now holds the post of Head of Microbiology.
PanTherix is an anti-infectives company using structure-guided drug design to discover and develop antibiotics acting on novel targets.

spacer
Anne Gill
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

Global Clinical Outsourcing Partnerships

26-27 March 2009, Mariott Hotel, Brussels

This Jacob Fleming event is designed to promote direct business. It features a two-day educational session with case studies, presentations and interactive sessions. This forum offers networking and the forging of new business partnerships in a unique business-driven environment.
More info >>

 
News and Press Releases

Azopharma Product Development Group, Inc

HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement